Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
June 19 2017 - 7:30AM
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR technology, today announced that China’s
State Intellectual Property Office (“SIPO”) has indicated that it
will grant a patent broadly covering CRISPR/Cas9 single-guide gene
editing methods and compositions. The patent includes claims
covering methods for editing DNA in non-cellular and cellular
settings, including in eukaryotic cells such as human and mammalian
cells. It also includes CRISPR/Cas9 composition of matter and
system claims for use in any setting, including claims covering the
use of CRISPR/Cas9 in producing medicines for treating disease.
“SIPO’s decision further expands our IP portfolio, and is
further global recognition that Jennifer Doudna, Emmanuelle
Charpentier and their team are the pioneers in the application of
CRISPR/Cas9 in all cell types,” said Intellia Therapeutics Chief
Executive Officer and President, Nessan Bermingham, Ph.D. “Intellia
continues to build on preclinical work and to focus on the
development of our pipeline of novel human therapeutics that will
potentially transform the lives of patients with genetic
diseases.”
The European Patent Office and the United Kingdom’s Intellectual
Property Office have previously issued patents from the same
underlying international patent application. This
international patent application is based on the same U.S. priority
applications that were filed starting in May 25, 2012 by the
Regents of the University of California, the University of Vienna
and Dr. Emmanuelle Charpentier (collectively, “the UC Intellectual
Property”). Intellia has rights to the UC Intellectual
Property, including the European and UK patents, for human
therapeutic, prophylactic, and palliative uses (including companion
diagnostics), excluding anti-fungal and anti-microbial
applications. Intellia obtained these rights through a 2014 license
agreement with Caribou Biosciences, Inc., which is the exclusive
licensee of the University of California and University of Vienna,
two of the co-owners of the intellectual property. In the
United States, certain patent claims from the UC Intellectual
Property were involved in an interference proceeding with patents
and patent applications owned by the Broad Institute et al. before
the U.S. Patent Trial and Appeal Board (“the PTAB”), and the PTAB
decision to terminate the interference is currently on appeal at
the U.S. Court of Appeals for the Federal Circuit.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on the
development of proprietary, potentially curative therapeutics using
the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by permanently
editing disease-associated genes in the human body with a single
treatment course. Intellia’s combination of deep scientific,
technical and clinical development experience, along with its
leading intellectual property portfolio, puts it in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; follow us on Twitter @intelliatweets.
Intellia’s Forward-Looking StatementThis press
release contains “forward-looking statements” of Intellia within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward looking statements include, but are not limited
to, express or implied statements regarding the intellectual
property position and strategy of Intellia’s licensors; and
Intellia’s ability to advance CRISPR/Cas9 into therapeutic products
for severe and life-threatening diseases and its CRISPR/Cas9
intellectual property portfolio. Any forward-looking statements in
this press release are based on management’s current expectations
of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks related to Intellia’s ability to
protect and maintain its intellectual property position, risks
related to the ability of Intellia’s licensors to protect and
maintain their intellectual property position, the risk that any
one or more of Intellia’s product candidates will not be
successfully developed and commercialized, the risk of cessation or
delay of any of the ongoing or planned clinical trials and/or
development of Intellia’s product candidates, the risk that the
results of previously conducted studies involving similar product
candidates will not be repeated or observed in ongoing or future
studies involving current product candidates, and the risk that
Intellia’s collaborations with Novartis or Regeneron will not
continue or will not be successful. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K filed
with the Securities and Exchange Commission, as well as discussions
of potential risks, uncertainties, and other important factors in
Intellia’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Intellia Therapeutics undertakes no duty to
update this information unless required by law.
Intellia Therapeutics
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Graeme Bell
Executive Vice President, Chief Financial Officer
+1 857-706-1071
graeme.bell@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024